Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Naturally Acquired Immunity versus Vaccine-induced Immunity, Reinfections versus Breakthrough Infections: A Retrospective Cohort Study

Cited by (283)

Items 201–283 of 283

1. Ómicron, un reset en la gestión de la pandemia
   Juan Simó Miñana · 2022 · Atención Primaria
2. Natural Infection of Omicron BA.5.2 in Patients Provides Broad Immune Responses Against SARS-CoV-2
   Le Li, Tang Feng, Quan Shen, Xiaoshan Shi, Zhigong Wei, Wanze Chen, Fan Yang, Yueting Zhu, Chengxin Zhang, Shuang Zhang et al. · 2025 · Microorganisms
3. Pfizer-BioNTech Coronavirus Disease 2019 Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 Infection Among Long-term Care Facility Staff With and Without Prior Infection in New York City, January–June 2021
   Kathryn Peebles, Robert J. Arciuolo, Anthony Romano, Jessica L. Sell, Sharon K. Greene, Sungwoo Lim, Candace Mulready-Ward, Alexandra Ternier, Brittan P Badenhop, Kathleen Blaney et al. · 2023 · The Journal of Infectious Diseases
4. Social contact in a pandemic: Rationality vs. heuristics
   Matthew S. Wilson · 2023 · Research in Economics
5. Does US full vaccination against COVID-19 immunize correspondingly S&P500 index: Evidence from the NARDL approach
   Hanen Atri, Hanen Teka, Saoussen Kouki · 2023 · Heliyon
6. The Influence of Initial Immunosuppression on the Kinetics of Humoral Response after SARS-CoV-2 Vaccination in Patients Undergoing Kidney Transplantation
   Renato Demarchi Foresto, Roberto Matias Souza, Gustavo Rodrigues dos Anjos, Mônica Rika Nakamura, Haryanne de Souza Goulart, Rayra Sampaio, Daniela Pereira França, Emanuelle Ferreira Marques, Elisabeth França Lucena, Marina Pontello Cristelli et al. · 2024 · Vaccines
7. Protection and waning of vaccine-induced, natural and hybrid immunity to SARS-CoV-2 in Hong Kong
   Jialiang Jiang, Kwok Fai Lam, Eric H. Y. Lau, Guosheng Yin, Yun Lin, Benjamin John Cowling · 2025 · Expert Review of Vaccines
8. Can a Multi-Epitope Vaccine be a solution for COVID-19 pandemic?
   Domina Petrić · 2021 · Academia Letters
9. Defining Antibody Seroprevalence and Duration of Humoral Responses to SARS-CoV-2 Infection and/or Vaccination in a Greek Community
   Ourania S. Kotsiou, Dimitrios Papagiannis, Εvangelos C. Fradelos, Dimitra S. Siachpazidou, Garyfallia Perlepe, Angeliki Miziou, Athanasios P. Kyritsis, George D. Vavougios, Georgios Kalantzis, Konstantinos I. Gourgoulianis · 2021 · International Journal of Environmental Research and Public Health
10. Mass vaccination in a roaring pandemic
    Giuseppe Gaeta · 2022 · Chaos Solitons & Fractals
11. Assessment of COVID-19 vaccination effectiveness
    Ewelina Stoczyńska-Fidelus, Piotr Rieske · 2022 · Alergologia Polska - Polish Journal of Allergology
12. Anticuerpos IgG determinados mediante ELISA desarrollados con antígenos de linajes Wuhan y Lambda en trabajadores de salud vacunados con BBIBP-CORV
    María García-Mendoza, Nancy Susy Merino-Sarmiento, Gabriel De Lucio-Burga, Manuel Fernández-Navarro, Luis Pampa-Espinoza, Gilmer Solis, Maribel Huaringa, Miryam Palomino, Pamela Rios, Lely Solari · 2022 · Revista Peruana de Medicina Experimental y Salud Pública
13. Environmental, biological and social factors contributing to new rises in COVID-19 morbidity in Russia
    Tatiana E. Sizikova, Vitaliy N. Lebedev, Sergey V. Borisevich · 2022 · Biological Products Prevention Diagnosis Treatment
14. SARS-CoV-2 Infection-Blocking Immunity Post Natural Infection: The Role of Vitamin D
    Rami Abu Fanne, Mahmud Moed, Aviv Kedem, Ghalib Lidawi, Emad Maraga, Fady Mohsen, Ariel Roguin, Simcha-Ron Meisel · 2023 · Vaccines
15. Evolution of seroprevalence to SARS‐CoV‐2 in blood donors in Sarajevo Canton, Federation of Bosnia and Herzegovina: Cross‐sectional and longitudinal studies
    Sanjin Musa, Elma Ćatović-Baralija, Veronica Ivey Sawin, Anthony Nardone, Mirza Palo, Siniša Skočibušić, Mia Blažević, Seila Lagarija, Gorana Ahmetović-Karić, Alma Ljuca et al. · 2023 · Influenza and Other Respiratory Viruses
16. Safety of AZD1222 COVID-19 vaccine and low Incidence of SARS-CoV-2 infection in Botswana following ChAdOx1(AZD1222) vaccination: A single-arm open-label interventional study – final study results
    Joseph M. Makhema, Emily Shava, Alane Izu, Tendani Gaolathe, Lesego Kuate, Adam Walker, Lucy Carty, Panayiotis Georgiou, Coulson Kgathi, Wonderful Tatenda Choga et al. · 2023 · IJID Regions
17. Utilizing direct and indirect information to improve the COVID-19 vaccination booster scheduling
    Yotam Dery, Matan Yechezkel, Irad Ben‐Gal, Dan Yamin · 2024 · Scientific Reports
18. COVID cure or perpetual vaccination?: 30 cheap effective treatments of COVID-19 & variants, like ivermectin, or never-ending compulsory injection, with unsafe, genotoxic, infertilizing, injuring, crippling, handicapping, lethal, inefficient, ineffective, abortion-tainted, abortive, unethical, experimental genetic-hacks, deceivingly called vaccines instead of haccines? Scientific proof of the COVID PLANdemic with 2000 peer reviewed published references.
    Federico A. Nazar · 2021
19. Heterologous vaccination as a strategy to minimize inequity in COVID-19 vaccine access: A modeling study in Thailand
    Suparinthon Anupong, T. Chantanasaro, C. Wilasang, N. C. Jitsuk, Chayanin Sararat, Kan Sornbundit, B. Pattanasiri, S. Chadsuthi, Charin Modchang · 2022 · medRxiv
20. On the concept and ethics of vaccination for the sake of others
    Steven R. Kraaijeveld · 2023
21. The Economics of Pandemics as a Globally Shared Experience: A Theory
    S. Niggol Seo · 2022 · Springer eBooks
22. A “disorder that exacerbates all other crises” or “a word we use to shut you up”? A critical policy analysis of NGOs’ discourses on COVID-19 misinformation
    Claudia Chaufan, Natalie Hemsing · 2025 · Open Health
23. Quantification of the IgG antibody response half-life for hybrid immunity to SARS-CoV-2
    Felicia Bongiovanni, Eamon J Conway, Lauren Smith, Jacob Cumming, Ramin Mazhari, Nicholas Kiernan‐Walker, Emily Marie Eriksson, Jodie McVernon, Ivo Müeller · 2025 · BMC Medicine
24. Pandemic Analysis II: Governmental Actions During the Pandemic—Lockdown or No Lockdown?
    S. Niggol Seo · 2022 · Springer eBooks
25. Back to the Future: Can Vaccines Win the Long-Term Fight Against COVID-19?
    Hildegund C.J. Ertl, Sue L. Currie, David M. Livermore · 2022 · Frontiers in Public Health
26. Milder outcomes of SARS-CoV-2 genetically confirmed reinfections compared to primary infections with the delta variant: A retrospective case-control study
    Alen Suljič, Maja Sočan, Maja Mrzel, Maja M. Lunar, Miša Korva, Alenka Štorman, Katarina Prosenc, Sandra Janežič, Tjaša Žohar Čretnik, Tina Zupanič et al. · 2022 · Frontiers in Medicine
27. Open Questions over the COVID-19 Pandemic
    Krešimir Pavelić, Sandra Kraljević Pavelić · 2023 · Science, Art and Religion.
28. National- and State-level SARS-CoV-2 Immunity Trends From January 2020 to December 2023: a Mathematical Modeling Analysis
    Fayette Klaassen, Nicole A. Swartwood, Melanie H. Chitwood, Rafael Lopes, Masahiko Haraguchi, Joshua A. Salomon, Ted Cohen, Nicolas A. Menzies · 2025 · The Journal of Infectious Diseases
29. The EU Digital COVID Certificate: Should We Differentiate Between Previously Infected and Fully Vaccinated People?
    José Gonçalo Marques · 2021 · Acta Médica Portuguesa
30. Guidelines for immunization of children following multisystem inflammatory syndrome in children
    Kamila Maria Ludwikowska, Magdalena Okarska‐Napierała, Agnieszka Matkowska‐Kocjan, Teresa Jackowska, Jacek Wysocki, Ernest Piotr Kuchar, Jarosław Władysław Peregud-Pogorzelski, Leszek Szenborn · 2022 · Pediatria Polska
31. SARS-CoV-2 spike IgG titres up to 137 days following Comirnaty mRNA COVID-19 vaccination, Israel, February to May 2021
    Tal Patalon, Shay Ben Moshe, Asaf Peretz, Ami Neuberger, Licita Schreiber, Rachel Lazar, Lia Supino‐Rosin, Galit Perez, Miri Mizrahi-Reuveni, Sivan Gazit · 2022 · Eurosurveillance
32. An Evaluation of Serological Tests to Determine Postvaccinal Immunity to SARS-CoV-2 by mRNA Vaccines
    Graciela Iglesias García, Ángel Díaz Rodríguez, Beatriz Díaz Fernández, C. Cuello Estrada, Tania García Ferreiro, Noelia Crespo García, Jesús Seco‐Calvo · 2022 · Journal of Clinical Medicine
33. Neutralising reactivity against SARS-CoV-2 B.1.617.2 (Delta) variant by vaccination status and pre-exposure
    Enrico Lavezzo, Monia Pacenti, Laura Manuto, Caterina Boldrin, Margherita Cattai, Marco Grazioli, Federico Bianca, Margherita Sartori, Federico Caldart, Gioele Castelli et al. · 2021 · Research Square
34. Impaired humoral immunity to BQ.1.1 in convalescent and vaccinated patients
    Felix Dewald, Martin Pirkl, Elvin Ahmadov, Martha Paluschinski, Joachim Kühn, Carina Elsner, Bianca Schulte, Maike Schlotz, Göksu Oral, Jacqueline Knüfer et al. · 2023 · medRxiv
35. Public Health Needs the Public Trust: A Pandemic Retrospective
    Matthew T. J. Halma, Joshua Guetzkow · 2023 · Preprints.org
36. The balance of risks and benefits in the COVID-19 “vaccine hesitancy” literature: An umbrella review
    Claudia Chaufan, Camila Heredia, Jennifer McDonald, Natalie Hemsing · 2023
37. Review of: "Factors influencing variable symptoms of COVID-19 patients and proposed revision of public policy for COVID-19 vaccination"
    Philip Oldfield · 2023
38. Is resisting Covid-19 vaccination a “problem”? A critical policy inquiry of vaccine mandates for healthcare workers
    Claudia Chaufan, Natalie Hemsing · 2024
39. SARS-CoV-2 epidemic in the South American Southern cone: can combined immunity from vaccination and infection prevent the spread of Gamma and Lambda variants while easing restrictions?
    Marcelo Fiori, Gonzalo Bello, Nicolás Wschebor, Federico Lecumberry, Andrés Ferragut, Ernesto Mordecki · 2021 · medRxiv
40. mRNA SARS-CoV2 Specific and Childhood Vaccines against Covid-19 Pandemic
    İdris Yazgan · 2021 · Türk doğa ve fen dergisi :/Türk doğa ve fen dergisi
41. Time to reinfection and vaccine breakthrough SARS-CoV-2 infections: a retrospective cohort study
    Sevda Molani, Andrew M. Baumgartner, Yeon Mi Hwang, Venkata R. S. K. Duvvuri, Jason D. Goldman, Jennifer Hadlock · 2022 · medRxiv
42. Some Yet Unresolved Questions and Mysteries About the COVID-19 Pandemic
    S. Niggol Seo · 2022 · Springer eBooks
43. Immunogenesis in patients with medium and severe coronavirus infection – dynamics in different age groups
    Petar Yordanov Atanasov, Stefka Achkova Ivanova, Yozlem Ali Kobakova, Maria Georgieva Moneva-Sakelarieva, Danka Petrova Obreshkova, Valentina Boyanova Petkova, Pavlina Yordanova-Laleva · 2022 · Pharmacia
44. Seroprevalence Surgery of Anti-SARS-CoV-2 Antibodies Based on COVID-19 Vaccine Type in Academy Community, East Kalimantan, Indonesia
    Swandari Paramita, Siti Khotimah, Marwan Marwan, Ronny Isnuwardana, Evi Fitriany, A. Z. Syadza Zahratun Nufus · 2022 · Open Access Macedonian Journal of Medical Sciences
45. Antibody avidity maturation favors SARS-CoV-2 convalescents over vaccinated individuals granting breadth in neutralizability and tolerance against variants
    Yu Nakagama, Katherine Candray, Natsuko Kaku, Yuko Komase, Maria-Virginia Rodriguez-Funes, Rhina Domínguez, Tomoya Tsuchida, Hiroyuki Kunishima, Etsuko Nagai, Eisuke Adachi et al. · 2022 · medRxiv
46. Usefulness and Limitations of Anti-S IgG Assay in Detecting Previous SARS-CoV-2 Breakthrough Infection in Fully Vaccinated Healthcare Workers
    Gianluca Spiteri, Maria Grazia Lourdes Monaco, Gulser Caliskan, Angela Carta, Maria Diletta Pezzani, Giuseppe Lippi, Davide Gibellini, Giuseppe Verlato, Stefano Porru · 2022 · Diagnostics
47. Obowiązek szczepień przeciw COVID-19: skuteczne narzędzie walki z pandemią czy bezpodstawny sanitaryzm?
    Piotr Witczak · 2022 · Wydawnictwo Naukowe Instytutu na rzecz Kultury Prawnej Ordo Iuris eBooks
48. Comparative IgG responses to SARS-CoV-2 after natural infection or vaccination
    Kaylan M. Olds, Devon P. Humphreys, Kathleen M. Gavin, Anne L. Wyllie, Timothy A. Bauer · 2022 · medRxiv
49. Likelihood of COVID-19 reinfection in an urban community cohort in Massachusetts
    Sharon M. Casey, Aaron Legler, Amresh D Hanchate, Rebecca B. Perkins · 2022 · Dialogues in Health
50. Antibody level against COVID-19 among the vaccinated infected and non-infected doctors by SARS-COV-2: A Comparative study
    Nazma Akhter, Forhadul Hoque Mollah, Nowrose Jahan, Jurdi Adam, Md Arif Hossain, Md Zaforullah Chowdhury · 2022 · Update Dental College Journal
51. Persistence of Neutralizing Antibodies and Clinical Protection up to 12 Months After Severe Acute Respiratory Syndrome Coronavirus 2 Infection in the Elderly
    Rocco Collarino, Christelle Vauloup‐Fellous, Aude Allemang‐Trivalle, Lina Mouna, Édouard Baudouin, Héloïse Keravec, Marie Neiss, Souhila Bouchareb, Cherif Bessai, Jorge Sanchez-Tamayo et al. · 2022 · Open Forum Infectious Diseases
52. Prior immunization status of COVID-19 patients and disease severity: A multicenter retrospective cohort study assessing the different types of immunity
    Javaria Aslam, Faisal Shahzad Khan, Muhammad Talha Haris, Hewad Hewadmal, Maryam Khalid, Mohammad Yahya Alshahrani, Qurrat-ul-ain Aslam, Irrum Aneela, Urooj Zafar · 2022 · Vaccine
53. The Omicron Variant of SARS-CoV-2 Virus: the Ability to Cause Disease in Persons with Immunity against COVID-19
    2022 · Journal of NBC Protection Corps
54. mRNA Vaccine Safety and Efficacy—Official Criteria When AEs Are Caused by the Injection
    Siguna Mueller · 2022 · Springer eBooks
55. Scales, Pseudoscales, the Human Factor, and a Way Forward
    Siguna Mueller · 2022 · Springer eBooks
56. References and Bibliography
    M. R. Islam, Jahanara Monaf, A.O. Islam · 2023 · Wiley eBooks
57. Rapidly Adaptable Multiplexed Yeast Surface Display Serological Assay for Immune Escape Screening of SARS-CoV-2 Variants
    Joanan López-Morales, Rosario Vanella, Tamara Utzinger, Valentin Schittny, Julia R. Hirsiger, Michael Friedrich Osthoff, Christoph T. Berger, Yakir Guri, Michael A. Nash · 2023 · medRxiv
58. Por una perspectiva crítica de la salud
    Iván Adolfo Natteri Romero · 2023 · Revista de Filosofía de la Universidad de Costa Rica
59. T- and B-cell Immune Response to COVID Vaccination in Liver Transplant Recipients Based on Interferon-gamma Release Assay and Serum Antibody Levels
    Premkumar DinuAbirami, Sugan Panneerselvam, K. Sampath Mouleeswaran, Govindarao Balajee, K. Premkumar, Srinivas Mettu Reddy, Joy Varghese · 2023 · Gastroenterology Hepatology and Endoscopy Practice
60. COVID-19 Antibody Testing in Healthcare Workers in Arkansas
    Manish Joshi, John W. Theus, Anita Joshi, Matthew C. Burns, Thaddeus C. Bartter · 2023 · Cureus
61. No evidence that ACE2 or TMPRSS2 drive population disparity in COVID risks
    Nathaniel Michael Pearson, John Novembre · 2023
62. Four change-makers seek impact in medical research
    Amy Coombs, Sandy Ong · 2024 · Nature
63. The Body Hack: Bringing the mRNA of COVID-19 Vaccines to the Right Cells at the Right Places
    Alberto A. Boretti · 2024 · Coronaviruses
64. Did The Implementation of Government Mandates Reduce COVID-19-Related Mortality Rates?
    Anthony Der Manulian · 2024 · American Journal of Biomedical Science & Research
65. No evidence that ACE2 or TMPRSS2 drive population disparity in COVID risks
    Nathaniel Michael Pearson, John Novembre · 2024 · BMC Medicine
66. Temporal Heterogeneous in the Effectiveness of Inactivated CoronaVac and Sinopharm Vaccines Against SARS‐CoV‐2 Reinfections in China
    Shihong Yang, Hualei Xin, Xingying Lang, Hua Jin, Xiaoman Cui, Lu Li, Chuchu Ye, Ying Qin, Yu Li, Benjamin John Cowling et al. · 2024 · Transboundary and Emerging Diseases
67. Covid-19 vaccination decisions and impacts of vaccine mandates: A cross sectional survey of healthcare workers in British Columbia, Canada
    Claudia Chaufan, Natalie Hemsing, Rachael Moncrieffe · 2024 · medRxiv
68. Role of COVID-19 infection status on the prediction of future infection: Immunity or susceptibility
    Fateme Nikbakht, Hamid Heidarian Miri, Ehsan Mosafarkhani, Fatemeh Sharifjafari, Ali Taghipour · 2025 · PLoS ONE
69. Comprehensive analysis of human coronavirus antibody responses in ICU and non-ICU COVID-19 patients reveals IgG3 against SARS-CoV-2 spike protein as a key biomarker of disease severity
    Fatma H. Ali, Giusy Gentilcore, Hadeel T. Al-Jighefee, Sara Taleb, Ali Ait Hssain, Hamda Abdulla Qotba, Asmaa A. Al Thani, Laith Jamal Abu-Raddad, Gheyath K. Nasrallah, Jean‐Charles Grivel et al. · 2025 · Journal of Medical Microbiology
70. Accelerated Biological Age as Predictor for Neutralizing Antibody Titers Against Sars-Cov-2 Virus Maintenance and Breakthrough Infection
    JengHow Yang, Chia-Lin Lee, Ya‐Fang Chiu, Sherry YuehHsia Chiu, LiJen Wang, Ting Wen Sheng, Shao-Chung Wang, ShuChun Huang, ShihHao Huang, ChangMei Lin et al. · 2025 · SSRN Electronic Journal
71. COVID-19 vaccine safety studies- the need for a third group for extended monitoring
    Upinder Kaur, Sankha Shubhra Chakrabarti · 2025 · Expert Opinion on Drug Safety
72. Estimating the impact of Covid-19 workplace vaccine mandates on employment status in the United States
    Alexandre de Figueiredo, Christos Andreas Makridis, Dionne M. Pohler, Rafael Gómez, Kevin Bardosh · 2025 · SSRN Electronic Journal
73. Correction: Impact of immune evasion, waning and boosting on dynamics of population mixing between a vaccinated majority and unvaccinated minority
    David N. Fisman, Afia Amoako, Alison E. Simmons, Ashleigh R. Tuite · 2025 · PLoS ONE
74. PhenoAge acceleration predicts antibody persistence and breakthrough infection after SARS-CoV-2 vaccination and infection
    Jeng‐How Yang, Chia-Lin Lee, Ya‐Fang Chiu, Sherry Yueh‐Hsia Chiu, Li-Jen Wang, Ting-Wen Sheng, Shao-Chung Wang, Shu-Chun Huang, Shih-Hao Huang, Chang-Mei Lin et al. · 2025 · Journal of Infection and Public Health
75. Protective Effectiveness of Sars-Cov-2 Infection Risk Among Hybrid, Vaccine, and Infection-induced Immunity Against the Omicron Variant, K-Serosmart
    Yifan Zhang, Won Chang, Kevin D. Dieckhaus, Suyoung Jo, Jina Han, Hye Jin Baek, Eunbi Noh, Kyuhyun Yoon, Jung Ae Kim, Jaehun Jung et al. · 2026 · Open Forum Infectious Diseases
76. Building a new arsenal: repurposed drugs and metronomic chemotherapy against medulloblastoma
    Caroline Donzé, Patricia Piris, Pierre Leblond, Mélanie Matteudi, Eddy Pasquier, Manon Carre, Nicolás André · 2026 · Expert Review of Neurotherapeutics
77. Étude des mécanismes d’action de nouveaux inhibiteurs de coronavirus humains
    Thomas Meunier · 2021
78. Stratégies d'immunothérapies basées sur des cellules dendritiques plasmacytoides : applications à la COVID-19 et au carcinome hépatocellulaire
    Anthony Maino · 2023 · theses.fr (ABES)
79. Feasibility of Capillary Self-Collected Blood Specimens for Routine Outpatient Laboratory Testing
    Chelsea B. Swartchick, Rachana Gurudu, Nathanael S Lexvold, Michael A. Lasho, Nikola A. Baumann, Darci R Block, Brooke M. Katzman, Jeffrey W. Meeusen · 2026 · The Journal of Applied Laboratory Medicine
80. Maternal immunization status and SARS-CoV-2 antibody transfer to neonates at birth
    Jesús Gilberto Gómez-Carballo, Refugio González-Losa, Laura Conde‐Ferráez, C. Cen-Baas, Nuvia Kantún-Moreno, H. Puerta-Guardo, José Antonio Cruz-Cárdenas, Marion E. G. Brunck, Y. Leal-Herrera, G. Valencia-Pacheco et al. · 2026 · Frontiers in Pediatrics
81. Seroprevalence Studies in the Albanian Population: Following the March Toward Herd Immunity (2020-2023)
    Genc Sulcebe, Erkena Shyti, Margarita Kurti-Prifti, Irena Seferi-Qendro, Alban Ylli, Melissa J. Perry · 2024 · Albanian Journal of Natural and Technical Sciences
82. Shopping Taxes and Covid
    Matthew S. Wilson · 2026 · Review of Economics
83. BindingDB Entry 50015147: Elastase Inhibitor Cyclotheonellazole A: Total Synthesis and In Vivo Biological Evaluation for Acute Lung Injury.
    BindingDB · 2023 · UC San Diego